Eric Benevich, Chief Commercial Officer at NEUROCRINE BIOSCIENCES INC (NBIX), sold 39,636 shares at $133.36 ($5.3M) on 2024-04-15, disclosed to the SEC on 2024-04-17.
Scheduled sale ($5.3M) by Chief Commercial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $133.36 | 7,231 | $964K | 18.2% |
| 2 | $133.36 | 7,231 | $964K | 18.2% |
| 3 | $133.36 | 12,587 | $1.7M | 31.8% |
| 4 | $133.36 | 12,587 | $1.7M | 31.8% |
| Total | $133.36 avg | 39,636 | $5.3M | 100% |
| Filing → |
| NBIX | SELL | 2025-02-14 | $503K | — | Filing → |
| NBIX | SELL | 2025-02-12 | $232K | — | Filing → |
| NBIX | SELL | 2025-02-04 | $369K | — | Filing → |